Sara M. Tolaney, MD, MPH, discusses newer approaches to managing early stages of HER2+ breast cancer in both the neoadjuvant and adjuvant spaces.
Investigator Perspectives
Follicular Lymphoma
Lung Cancer
Colorectal Cancer
Chronic Lymphocytic Leukemia
Multiple Myeloma
Multiple Myeloma
Chronic Lymphocytic Leukemia
Graft versus Host Disease
Ovarian Cancer
Non-Hodgkin Lymphoma
Prostate Cancer
Graft versus Host Disease
Graft versus Host Disease
Graft versus Host Disease
Follicular Lymphoma
Multiple Myeloma
Bladder Cancer
Chronic Lymphocytic Leukemia
Colorectal Cancer
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
3
Lurbinectedin Contributes to Maintenance of Response in ES-SCLC
4
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
5
